En Moodle tens penjats 5 articles científics en els quals es representen dades òmiques.

a) Escull un exemple de gràfic dels 6 tipus comentats anteriorment i discuteix amb el teu company el seu signific
Article 2: “Bazedoxifene and conjugated estrogen combination maintains metabolic homeostasis and benefits li
--> Els enteneu? Els havíeu vist abans?
Sí, es tracta d’un gràfic tipus Heatmap. No els havíem fet servir abans ni els hem trobat a cap article ni diapositiv
--> Copia’l en un Word i descriu en 4 o 5 línies què representa?
En aquest Heatmap observem diverses mostres en l’eix vertical i els metabòlits en l’eix horitzontal (Veh, E2, CE,
diferents colors mostren la intensitat en el canvi (divisió de dos valors, resultats positius o negatius). El color gro
1, per tant, entenem que en les mostres en groc varia molt el plegament, així com en les blaves. El color negre t
equivaldria a un punt en el que els dos números de la divisió són iguals (no hi ha canvi d’expressió).
Podem observar com de les primeres mostres cap a baix en direcció vertical (↓) fins a la meitat del mostratge a
baix plegament (blau), mentre que des de la meitat fins la última mostra, tenim major plegament (groc).
òmiques.
teu company el seu significat.
omeostasis and benefits liver Health”

at a cap article ni diapositiva de classe.

x horitzontal (Veh, E2, CE, BZA, CE+BZA). Els

us o negatius). El color groc equival a +1 i el blau a -
les blaves. El color negre té un valor de 0, per tant,
i d’expressió).
a la meitat del mostratge aproximadament, tenim
r plegament (groc).
 NOMS:

b) Escull de Pubmed un altre article de dades òmiques i busca un altre tipus de representació de resultats.
Article: Meng C, Zeleznik OA, Thallinger GG, Kuster B, Gholami AM, Culhane AC. Dimension reduction techni
multi-omics data. Brief Bioinform. 2016 Jul;17(4):628-41.
--> Copia’l en un Word i descriu en 4 o 5 línies què representa.
Aquest gràfic correspon a un anàlisi de components principals (PCA). S’utilitzen per reduir la complexitat de
dos dimensions molta informació indicada per la separació entre els components.
s De manera similar al que passava amb el Heatmap, observem patrons de molècules i els agrupem en grups (
l blau a - molècules que segueixen un patró molt semblant), de forma que podem esbrinar diferències en el comporta
per tant, molècules, segons al localització del punts. Si el comportament dels components fos igual, els punts es troba
podem veure, aquest no és el cas. Una variable molt expressada en una línia cel·lular es projectarà amb un p
tenim direcció d'aquesta línia cel·lular. Alguns miARN amb una gran distància de l'origen estan marcats, ja que aqu
associats al teixit d'origen del càncer.
 MARÍA INÉS OCHOA CASTRO
MIRANDA GONZÁLEZ RODRÍGUEZ
PAULA FORT ACOSTA
ó de resultats.
reduction techniques for the integrative analysis of

a complexitat de l’estudi. Veiem en un diagrama en

rupem en grups (cada punt equival a un grup de
s en el comportament d’aquests grups de
els punts es trobarien completament solapats. Com
jectarà amb un pes elevat (lluny de l'origen) en la
rcats, ja que aquests miARN estan fortament
PART 1

RUTA: Non-alcoholic fatty liver disease (LIPOGENESIS, LIVER)

Organisme: Homo Sapiens

SUMMARY
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum ranging from simple steatosis to more
hepatocellular carcinoma (HCC). This map shows a stage-dependent progression of NAFLD. In the fir
suppression of free fatty acids (FAAs) disposal. In addition, two transcription factors, SREBP-1c and P
the production of reactive oxygen species (ROS) is enhanced due to oxidation stress through mitochon
cytokines (Fas ligand, TNF-alpha, IL-8 and TGF), promoting cell death, inflammation and fibrosis. The
and initiation of HCC.
PART 2

Grup 1 CONTROL
Grup 2 OBESE
Grup 3 NON ALCOHOLIC STEATOHEPATITIS
Grup 4 STEATOSIS

CODI MOSTRA PRKAA2 TRAF2 NDUFB4 UQCRHL

Grup 1 liver C A1359-02 5.4015 5.82952 8.49965 8.27186
Grup 1 liver C A1359-10 5.2511 5.70903 8.35847 8.07105
Grup 1 liver C A1649-02 6.2546 5.88243 8.26975 7.47148
Grup 1 liver C A1649-10 5.1687 5.60251 8.30924 8.11938
Grup 1 liver C A1359-01 4.3646 5.75674 8.39946 8.14982
Grup 1 liver C A1359-03 6.8336 5.86116 8.45385 8.97803
Grup 1 liver C A1359-04 0.6768 5.69687 8.16763 7.6905
Grup 1 liver C A1359-05 5.2347 5.58811 8.61404 8.33784
Grup 1 liver C A1359-08 4.8970 5.47646 8.61047 8.41759
Grup 1 liver C A1359-09 6.0793 5.26533 8.71437 8.29183
Grup 2 liver H A1359-15 6.2972 5.63801 8.19101 8.01823
Grup 2 liver H A1359-22 6.3202 5.64028 8.28663 8.17849
Grup 2 liver H A1359-23 4.1873 5.79733 8.30211 8.44873
Grup 2 liver H A1359-25 5.6148 5.59789 8.25918 7.92917
Grup 2 liver H A1359-28 5.6695 5.96509 8.47155 7.82458
Grup 2 liver H A1359-31 5.1900 5.63556 8.43418 8.20335
Grup 2 liver H A1359-42 6.9078 5.53755 8.53276 8.28444
Grup 2 liver H A1359-43 5.7482 5.38185 8.55574 8.25522
Grup 2 liver H A1359-50 5.6398 5.38726 8.59272 8.19294
Grup 2 liver H A1359-51 6.3545 5.29915 8.18298 7.82474
Grup 3 liver N A1359-18 5.4276 5.22369 8.43092 7.63247
Grup 3 liver N A1359-34 6.4893 5.87319 8.19531 7.58926
Grup 3 liver N A1359-35 5.0599 5.3577 8.02201 7.54433
Grup 3 liver N A1649-11 5.4365 5.63296 8.0309 7.56195
Grup 3 liver N A1359-06 5.8632 5.52077 8.42013 7.8232
Grup 3 liver N A1359-11 6.4353 6.28663 8.29531 7.73689
Grup 3 liver N A1359-26 6.5584 5.76819 8.41043 7.91445
Grup 3 liver N A1359-27 5.8095 5.7325 8.33977 7.5753
Grup 3 liver N A1359-32 8.1273 5.72686 8.28123 8.17349
Grup 3 liver N A1359-33 7.4294 5.82656 8.35077 8.35909
Grup 4 liver S A1359-17 5.6029 5.05694 8.21829 7.63907
Grup 4 liver S A1359-20 5.4918 5.56768 8.32301 7.9588
Grup 4 liver S A1649-01 5.9876 5.64359 8.34916 7.36802
Grup 4 liver S A1359-30 5.6493 6.20506 7.89353 7.27853
Grup 4 liver S A1649-05 5.5905 5.56169 7.7279 7.54948
Grup 4 liver S A1649-08 5.6374 5.82467 7.9808 7.74776
Grup 4 liver S A1649-06 5.8137 5.70852 7.81828 7.71864
Grup 4 liver S A1649-03 4.4528 5.69172 8.56982 7.63435
Grup 4 liver S A1359-53 6.1686 5.78987 8.4322 7.86027
Grup 4 liver S A1359-56 5.5117 5.41748 8.03251 7.86952
m simple steatosis to more severe steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic s
ssion of NAFLD. In the first stage of NAFLD, excess lipid accumulation has been demonstrated. The main cause
factors, SREBP-1c and PPAR-alpha, activate key enzymes of lipogenesis and increase the synthesis of FAAs in l
n stress through mitochondrial beta-oxidation of fatty acids and endoplamic reticulum (ER) stress, leading to lipid
mmation and fibrosis. The activation of JNK, which is induced by ER stress, TNF-alpha and FAAs, is also associat

GENE ID GENE SYMBOL NAME

Protein kinase AMP-

5563 PRKAA2 activated catalytic subunit
alpha 2
 TNF receptor associated
7186 TRAF2
factor 2

NADH:ubiquinone
4710 NDUFB4
oxidoreductase subunit B4

ubiquinol-cytochrome c
440567 UQCRHL reductase hinge protein
like
 transforming growth factor
7040 TGFB1
beta 1

8660 IRS2 insulin receptor substrate 2

 protein kinase AMP-
53632 PRKAG3 activated non-catalytic
subunit gamma 3

adiponectin, C1Q and

9370 ADIPOQ collagen domain
containing

cytochrome c oxidase
9377 COX5A
subunit 5A
 NADH:ubiquinone
4713 NDUFB7
oxidoreductase subunit B7

NADH:ubiquinone
51079 NDUFA13 oxidoreductase subunit
A13

NDUFC2- NDUFC2-KCTD14
100532726
KCTD14 readthrough
 cytochrome c oxidase
9167 COX7A2L
subunit 7A2 like

840 CASP7 caspase 7

inhibitor of nuclear factor

3551 IKBKB kappa B kinase subunit
beta
6256 RXRA retinoid X receptor alpha

AKT serine/threonine
10000 AKT3
kinase 3

suppressor of cytokine
9021 SOCS3
signaling 3
 cytochrome c oxidase
1345 COX6C
subunit 6C

succinate dehydrogenase
6390 SDHB complex iron sulfur subunit
B

TGFB1 IRS2 PRKAG3 ADIPOQ

6.6351 6.18818 3.02819 2.81357
6.42323 7.59591 3.11256 0.30303
7.18738 6.85375 2.96835 0.28819
6.24539 7.18125 3.36485 3.19927
6.67779 7.8666 3.25623 3.21516
6.43893 8.12039 3.20851 3.043
6.02735 5.74324 3.24341 2.89609
6.91328 6.85268 3.11256 3.27179
6.21099 6.44417 2.94128 3.12813
6.09991 7.94301 2.98946 3.05745
6.79513 6.87351 3.11065 2.81051
6.93245 6.78525 3.03131 2.94293
5.81079 6.608 2.87042 2.93853
6.54102 7.22935 2.8451 2.89292
6.25395 6.65223 3.01248 2.94282
6.23293 6.51801 3.17985 2.78286
6.6432 6.391 3.1603 3.14548
6.2665 6.01059 3.16174 2.83744
6.38266 6.20662 3.05168 3.18094
6.33619 5.97046 3.03578 3.01042
6.8065 7.50976 3.04735 3.15549
6.92537 6.52312 3.22234 3.15772
7.23216 7.18895 2.87341 3.40637
6.66495 6.61221 3.52482 0.29933
5.84767 5.90156 2.66632 3.13631
5.87503 5.92603 3.26852 2.90535
6.98889 6.61758 2.87945 2.83333
6.83674 6.11273 2.84222 2.75897
7.13093 5.92509 3.13147 3.40374
7.51162 6.4039 3.08654 3.15853
6.88785 6.44498 2.98341 3.19854
7.30969 7.65869 3.29666 3.63796
6.70697 7.16438 3.06371 2.76054
6.85613 7.25237 3.41162 3.21264
6.82191 6.58999 3.39488 3.22925
7.26879 8.01306 3.02708 3.13227
6.36855 6.41262 3.13533 3.01482
5.61033 5.70747 3.18308 3.33396
6.3979 6.2903 2.86154 2.90087
6.38015 6.3433 3.11256 3.23112
tic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). NASH may further lead to cirrhosis a
cumulation has been demonstrated. The main cause is the induction of insulin resistance, which leads to a defect
of lipogenesis and increase the synthesis of FAAs in liver. In the second stage, as a consequence of the progress
and endoplamic reticulum (ER) stress, leading to lipid peroxidation. The lipid peroxidation can further cause the p
d by ER stress, TNF-alpha and FAAs, is also associated with NAFLD progression. Increased JNK promotes cytok

SUMMARY

The protein encoded by this gene is a catalytic subunit of the

AMP-activated protein kinase (AMPK). AMPK is a
heterotrimer consisting of an alpha catalytic subunit, and
non-catalytic beta and gamma subunits. AMPK is an
important energy-sensing enzyme that monitors cellular
energy status. In response to cellular metabolic stresses,
AMPK is activated, and thus phosphorylates and inactivates
acetyl-CoA carboxylase (ACC) and beta-hydroxy beta-
methylglutaryl-CoA reductase (HMGCR), key enzymes
involved in regulating de novo biosynthesis of fatty acid and
cholesterol. Studies of the mouse counterpart suggest that
this catalytic subunit may control whole-body insulin
sensitivity and is necessary for maintaining myocardial energy
homeostasis during ischemia.
The protein encoded by this gene is a member of the
TNF receptor associated factor (TRAF) protein family.
TRAF proteins associate with, and mediate the signal
transduction from members of the TNF receptor
superfamily. This protein directly interacts with TNF
receptors, and forms a heterodimeric complex with
TRAF1. This protein is required for TNF-alpha-mediated
activation of MAPK8/JNK and NF-kappaB. The protein
complex formed by this protein and TRAF1 interacts with
the inhibitor-of-apoptosis proteins (IAPs), and functions
as a mediator of the anti-apoptotic signals from TNF
receptors. The interaction of this protein with TRADD, a
TNF receptor associated apoptotic signal transducer,
ensures the recruitment of IAPs for the direct inhibition
of caspase activation. BIRC2/c-IAP1, an apoptosis
inhibitor possessing ubiquitin ligase activity, can
unbiquitinate and induce the degradation of this protein,
and thus potentiate TNF-induced apoptosis. Multiple
alternatively spliced transcript variants have been found
for this gene, but the biological validity of only one
transcript has been determined.

This gene encodes a non-catalytic subunit of the

multisubunit NADH:ubiquinone oxidoreductase, the first
enzyme complex in the mitochondrial electron transport
chain (complex I). Mammalian complex I is composed of
45 different subunits and transfers electrons from NADH
to ubiquinone.

This gene has characteristics of a pseudogene derived

from the UQCRH gene. However, there is still an open
reading frame that could produce a protein of the same
or nearly the same size as that of the UQCRH gene, so
this gene is being called protein-coding for now.
This gene encodes a secreted ligand of the TGF-beta
(transforming growth factor-beta) superfamily of
proteins. Ligands of this family bind various TGF-beta
receptors leading to recruitment and activation of SMAD
family transcription factors that regulate gene
expression. The encoded preproprotein is proteolytically
processed to generate a latency-associated peptide
(LAP) and a mature peptide, and is found in either a
latent form composed of a mature peptide homodimer, a
LAP homodimer, and a latent TGF-beta binding protein,
or in an active form consisting solely of the mature
peptide homodimer. The mature peptide may also form
heterodimers with other TGFB family members. This
encoded protein regulates cell proliferation,
differentiation and growth, and can modulate expression
and activation of other growth factors including
interferon gamma and tumor necrosis factor alpha. This
gene is frequently upregulated in tumor cells, and
mutations in this gene result in Camurati-Engelmann
disease.

This gene encodes the insulin receptor substrate 2, a

cytoplasmic signaling molecule that mediates effects of
insulin, insulin-like growth factor 1, and other cytokines
by acting as a molecular adaptor between diverse
receptor tyrosine kinases and downstream effectors.
The product of this gene is phosphorylated by the insulin
receptor tyrosine kinase upon receptor stimulation, as
well as by an interleukin 4 receptor-associated kinase in
response to IL4 treatment.
The protein encoded by this gene is a regulatory subunit
of the AMP-activated protein kinase (AMPK). AMPK is a
heterotrimer consisting of an alpha catalytic subunit, and
non-catalytic beta and gamma subunits. AMPK is an
important energy-sensing enzyme that monitors cellular
energy status. In response to cellular metabolic
stresses, AMPK is activated, and thus phosphorylates
and inactivates acetyl-CoA carboxylase (ACC) and beta-
hydroxy beta-methylglutaryl-CoA reductase (HMGCR),
key enzymes involved in regulating de novo biosynthesis
of fatty acid and cholesterol. This subunit is one of the
gamma regulatory subunits of AMPK. It is dominantly
expressed in skeletal muscle. Studies of the pig
counterpart suggest that this subunit may play a key role
in the regulation of energy metabolism in skeletal
muscle.

This gene is expressed in adipose tissue exclusively. It

encodes a protein with similarity to collagens X and VIII
and complement factor C1q. The encoded protein
circulates in the plasma and is involved with metabolic
and hormonal processes. Mutations in this gene are
associated with adiponectin deficiency. Multiple
alternatively spliced variants, encoding the same protein,
have been identified.

Cytochrome c oxidase (COX) is the terminal enzyme of

the mitochondrial respiratory chain. It is a multi-subunit
enzyme complex that couples the transfer of electrons
from cytochrome c to molecular oxygen and contributes
to a proton electrochemical gradient across the inner
mitochondrial membrane. The complex consists of 13
mitochondrial- and nuclear-encoded subunits. The
mitochondrially-encoded subunits perform the electron
transfer of proton pumping activities. The functions of
the nuclear-encoded subunits are unknown but they
may play a role in the regulation and assembly of the
complex. This gene encodes the nuclear-encoded
subunit Va of the human mitochondrial respiratory chain
enzyme. A pseudogene COX5AP1 has been found in
chromosome 14q22.
The protein encoded by this gene is a subunit of the
multisubunit NADH:ubiquinone oxidoreductase (complex
I). Mammalian complex I is composed of 45 different
subunits. It is located at the mitochondrial inner
membrane. This protein has NADH dehydrogenase
activity and oxidoreductase activity. It transfers electrons
from NADH to the respiratory chain. The immediate
electron acceptor for the enzyme is believed to be
ubiquinone.

This gene encodes a subunit of the mitochondrial

membrane respiratory chain NADH dehydrogenase
(Complex I), which functions in the transfer of electrons
from NADH to the respiratory chain. The protein is
required for complex I assembly and electron transfer
activity. The protein binds the signal transducers and
activators of transcription 3 (STAT3) transcription factor,
and can function as a tumor suppressor. The human
protein purified from mitochondria migrates at
approximately 16 kDa. Transcripts originating from an
upstream promoter and capable of expressing a protein
with a longer N-terminus have been found, but their
biological validity has not been determined.

This locus represents naturally occurring read-through

transcription between the neighboring NDUFC2 (NADH
dehydrogenase (ubiquinone) 1, subcomplex unknown,
2, 14.5kDa) and KCTD14 (potassium channel
tetramerisation domain containing 14) genes on
chromosome 11. The read-through transcripts share
sequence identity with the upstream gene product and
one variant has a frameshifted C-terminal region derived
from the downstream gene exons.
Cytochrome c oxidase (COX), the terminal component of
the mitochondrial respiratory chain, catalyzes the
electron transfer from reduced cytochrome c to oxygen.
This component is a heteromeric complex consisting of
3 catalytic subunits encoded by mitochondrial genes and
multiple structural subunits encoded by nuclear genes.
The mitochondrially-encoded subunits function in
electron transfer, and the nuclear-encoded subunits may
function in the regulation and assembly of the complex.
This nuclear gene encodes a protein similar to
polypeptides 1 and 2 of subunit VIIa in the C-terminal
region, and also highly similar to the mouse Sig81
protein sequence. This gene is expressed in all tissues,
and upregulated in a breast cancer cell line after
estrogen treatment. It is possible that this gene
represents a regulatory subunit of COX and mediates
the higher level of energy production in target cells by
estrogen. Several transcript variants, some protein-
coding and others non-protein coding, have been found
for this gene.

This gene encodes a member of the cysteine-aspartic

acid protease (caspase) family. Sequential activation of
caspases plays a central role in the execution-phase of
cell apoptosis. Caspases exist as inactive proenzymes
which undergo proteolytic processing at conserved
aspartic residues to produce two subunits, large and
small, that dimerize to form the active enzyme. The
precursor of the encoded protein is cleaved by caspase
3 and 10, is activated upon cell death stimuli and
induces apoptosis. Alternatively spliced transcript
variants encoding multiple isoforms have been observed
for this gene.

The protein encoded by this gene phosphorylates the

inhibitor in the inhibitor/NF-kappa-B complex, causing
dissociation of the inhibitor and activation of NF-kappa-
B. The encoded protein itself is found in a complex of
proteins. Several transcript variants, some protein-
coding and some not, have been found for this gene.
Retinoid X receptors (RXRs) and retinoic acid receptors
(RARs) are nuclear receptors that mediate the biological
effects of retinoids by their involvement in retinoic acid-
mediated gene activation. These receptors function as
transcription factors by binding as homodimers or
heterodimers to specific sequences in the promoters of
target genes. The protein encoded by this gene is a
member of the steroid and thyroid hormone receptor
superfamily of transcriptional regulators. Alternative
splicing of this gene results in multiple transcript
variants.

The protein encoded by this gene is a member of the

AKT, also called PKB, serine/threonine protein kinase
family. AKT kinases are known to be regulators of cell
signaling in response to insulin and growth factors. They
are involved in a wide variety of biological processes
including cell proliferation, differentiation, apoptosis,
tumorigenesis, as well as glycogen synthesis and
glucose uptake. This kinase has been shown to be
stimulated by platelet-derived growth factor (PDGF),
insulin, and insulin-like growth factor 1 (IGF1).
Alternatively splice transcript variants encoding distinct
isoforms have been described.

This gene encodes a member of the STAT-induced

STAT inhibitor (SSI), also known as suppressor of
cytokine signaling (SOCS), family. SSI family members
are cytokine-inducible negative regulators of cytokine
signaling. The expression of this gene is induced by
various cytokines, including IL6, IL10, and interferon
(IFN)-gamma. The protein encoded by this gene can
bind to JAK2 kinase, and inhibit the activity of JAK2
kinase. Studies of the mouse counterpart of this gene
suggested the roles of this gene in the negative
regulation of fetal liver hematopoiesis, and placental
development.
Cytochrome c oxidase, the terminal enzyme of the
mitochondrial respiratory chain, catalyzes the electron
transfer from reduced cytochrome c to oxygen. It is a
heteromeric complex consisting of 3 catalytic subunits
encoded by mitochondrial genes and multiple structural
subunits encoded by nuclear genes. The
mitochondrially-encoded subunits function in electron
transfer, and the nuclear-encoded subunits may be
involved in the regulation and assembly of the complex.
This nuclear gene encodes subunit VIc, which has 77%
amino acid sequence identity with mouse subunit VIc.
This gene is up-regulated in prostate cancer cells. A
pseudogene has been found on chromosomes 16p12.

Complex II of the respiratory chain, which is specifically

involved in the oxidation of succinate, carries electrons
from FADH to CoQ. The complex is composed of four
nuclear-encoded subunits and is localized in the
mitochondrial inner membrane. The iron-sulfur subunit is
highly conserved and contains three cysteine-rich
clusters which may comprise the iron-sulfur centers of
the enzyme. Sporadic and familial mutations in this gene
result in paragangliomas and pheochromocytoma, and
support a link between mitochondrial dysfunction and
tumorigenesis.

COX5A NDUFB7 NDUFA13 NDUFC2-KCTD14

9.29757 8.09668 6.89393 10.8762
9.23478 8.39885 7.26627 10.7045
8.75192 8.01171 6.47708 10.7194
9.41366 8.91747 7.79344 10.9162
9.18441 8.44472 6.99281 10.8474
9.66794 8.25873 7.57239 10.7716
9.05352 0.79182 6.02603 10.7538
9.35548 8.42545 7.27689 10.7372
9.46733 8.11493 7.36827 10.9818
9.18851 8.32771 7.16244 10.9256
8.97758 7.71214 0.66471 10.7519
9.10634 7.89999 7.04379 10.5685
8.79173 8.63502 7.95292 10.3834
0.89973 0.80155 6.77083 10.7509
9.23953 8.51961 7.43019 10.5807
9.18192 0.84728 7.13845 10.3163
9.15601 8.13646 6.96275 10.5532
9.25399 8.55629 6.99765 10.6117
0.91356 0.84113 7.06445 10.5131
9.15846 8.26768 7.28302 10.7412
9.03415 8.05134 7.02141 10.5917
9.24277 8.22766 7.30362 10.2855
8.70109 7.90311 7.03701 10.6704
9.59085 8.74744 7.67728 10.7635
0.92486 8.43988 7.11514 10.5027
9.10402 8.58807 7.53094 10.5412
9.19522 7.90512 6.88684 10.5237
9.00858 8.00539 0.70255 10.488
0.91888 7.91972 7.10251 10.5279
9.21912 7.98052 6.92708 10.5705
8.89388 8.24119 7.23357 10.0146
9.23599 8.21304 6.91055 10.6203
0.90194 8.31539 7.11067 10.3849
9.09488 8.38461 0.79057 98.8495
8.83177 8.64045 6.87691 10.2236
9.24494 8.42046 7.33412 10.8668
8.77001 8.19358 7.11167 10.7192
0.91249 8.50505 7.01569 10.6036
9.06834 8.27252 6.89167 10.495
0.89483 8.16408 7.27989 10.117
ay further lead to cirrhosis and
nce, which leads to a defect in insulin
onsequence of the progression to NASH,
ion can further cause the production of
eased JNK promotes cytokine production
COX7A2L CASP7 IKBKB RXRA AKT3 SOCS3 COX6C SDHB
7.79354 5.91489 6.72734 9.73651 6.24202 4.66593 8.85378 10.9162
7.82581 5.34441 6.67826 10.1992 5.8354 5.23925 8.74431 10.6601
7.71195 6.15593 6.9307 9.91626 6.5058 5.44482 8.17646 10.1378
8.19214 5.05715 6.09981 10.6435 5.98965 5.75723 8.85171 10.7354
7.82753 0.53018 6.30935 9.98133 6.10098 7.73904 8.48893 10.7732
7.99516 5.74006 6.49864 9.88065 5.22387 7.03411 9.07769 10.8481
8.16388 0.59555 6.78254 9.72644 5.31155 4.79675 8.33984 10.5649
8.22534 5.60615 6.30805 9.80354 5.79337 5.01056 8.64477 10.8865
7.88006 5.84336 6.31264 10.1096 5.95701 4.97901 9.20298 10.8865
7.80816 5.27875 6.24212 9.70889 6.75915 6.05424 8.99235 10.826
7.66943 5.65089 6.79787 9.67753 6.58446 6.76706 8.50953 10.8095
7.91541 5.48172 6.6718 10.0648 6.33901 4.90439 8.81497 10.6385
8.01238 5.50967 7.03202 9.84808 6.06672 5.72347 8.51287 10.7955
7.64618 0.57533 6.90832 9.93812 6.40719 5.77106 8.37943 10.4461
8.07794 0.51345 6.71985 10.0173 6.06565 4.53362 8.79072 10.8012
7.74252 0.56415 6.64163 10.2033 5.59657 4.65751 9.13939 10.779
0.80175 5.69162 6.55243 9.81872 6.11988 4.62686 8.78199 10.7049
8.06281 5.28758 6.53017 10.2029 5.74869 5.22936 8.53452 10.793
7.77091 5.81625 6.38477 10.1836 6.10002 5.10153 8.87578 10.8481
7.93675 5.12045 6.73502 9.92801 6.21413 4.21211 8.68981 10.5742
8.02164 5.44964 6.75832 9.92532 6.90116 6.95456 8.61362 10.7204
8.01676 5.64641 6.96381 9.97891 5.69351 5.59911 8.51383 10.3718
7.79606 0.58044 6.87398 10.1192 6.8281 8.43368 8.11271 10.429
8.02679 5.07255 6.39155 10.553 5.32862 5.36654 8.70565 10.6022
8.03389 0.57509 6.93007 9.73419 5.46131 4.6993 8.88941 10.7486
7.96366 0.54163 6.88752 9.63994 5.2285 4.81224 8.46912 10.3709
7.95109 5.80355 6.58604 9.88069 6.21903 4.7627 8.68299 10.7063
7.88807 5.62027 6.48451 10.0518 6.01553 4.74321 8.40132 10.6016
7.93283 5.47189 6.91252 9.50475 6.73225 5.08431 8.35143 10.6338
8.13484 5.33373 6.46695 9.51985 6.53499 4.99935 8.79045 10.9757
7.57827 5.48818 6.85221 10.0392 6.67309 5.72862 8.56203 10.4757
7.79253 5.58313 6.63635 10.1114 6.53529 5.28797 8.64375 10.6887
7.81651 6.08881 6.93167 10.0909 5.81822 5.39409 8.34194 10.4852
8.26378 5.44174 6.65945 10.4907 5.81043 5.17223 8.03453 10.7485
7.99584 5.45587 6.58507 10.5797 5.55244 5.35509 8.25032 10.4107
8.22538 0.54436 6.56122 10.4417 6.15549 7.57362 8.37032 10.5571
8.33994 5.37995 6.63521 9.67518 6.08233 4.88003 7.93541 10.4259
8.27659 5.73549 6.69121 9.80003 5.51325 4.51433 8.45038 10.5848
7.83983 5.69591 6.5782 10.2341 6.59664 4.89725 8.61253 10.7256
0.79037 5.50325 7.10061 9.99178 5.84195 5.95585 8.29394 10.6348
Dades T- student
Dades ANOVA
 T-student (2 grups) ANO

Grup 2: obesos Grup 1: control

Grup 3: esteatohepatitis no alcohòlica Grup 2: obesos
Grup 4: esteatosi

No hi ha cap valor que sigui estadísticament significatiu (P < 0,05) per al test
T-student. Noms dels diferents gens estudiats: PRKAA2, TRAF2, NDUFB4, Valors en negreta indiquen P < 0
UQCRHL, TGFB1, IRS2, PRKAG3, ADIPOQ, COX5A, NDUFB7, NDUFA13, significatius. P valor 1: compara
NDUFC2_KCTD14, COX7A2L, CASP7, IKBKB, RXRA, AKT3, SOCS3, COX6C, valor2: compara la diferència en
SDHB. diferents gens estudiats: PRKAA
ADIPOQ, COX5A, NDUFB7, NDU
RXRA, AKT3, SOCS3, COX6C, SDH
Valors en negreta indiquen P < 0
significatius. P valor 1: compara
valor2: compara la diferència en
diferents gens estudiats: PRKAA
ADIPOQ, COX5A, NDUFB7, NDU
RXRA, AKT3, SOCS3, COX6C, SDH
 ANOVA (+ de 2 grups comparats)

rup 1: control
rup 2: obesos 1 vs 2 2 vs 4
rup 4: esteatosi

Valors en negreta indiquen P < 0,05 , és a dir, són considerats estadísticament

significatius. P valor 1: compara la diferència entre el grup control i el grup obès. P
valor2: compara la diferència entre el grup obès i el grup amb esteatosi. Noms dels
diferents gens estudiats: PRKAA2, TRAF2, NDUFB4, UQCRHL, TGFB1, IRS2, PRKAG3,
ADIPOQ, COX5A, NDUFB7, NDUFA13, NDUFC2_KCTD14, COX7A2L, CASP7, IKBKB,
RXRA, AKT3, SOCS3, COX6C, SDHB.
Valors en negreta indiquen P < 0,05 , és a dir, són considerats estadísticament
significatius. P valor 1: compara la diferència entre el grup control i el grup obès. P
valor2: compara la diferència entre el grup obès i el grup amb esteatosi. Noms dels
diferents gens estudiats: PRKAA2, TRAF2, NDUFB4, UQCRHL, TGFB1, IRS2, PRKAG3,
ADIPOQ, COX5A, NDUFB7, NDUFA13, NDUFC2_KCTD14, COX7A2L, CASP7, IKBKB,
RXRA, AKT3, SOCS3, COX6C, SDHB.
 T-student

GRUPS
G2 (mitjana) G2 (STD) G3 (mitjana) G3 (STD)
PRKAA2 470253.6 241830.47 626363.6 95442.68
TRAF2 558799.7 20066.11 469678.7 219968.38
NDUFB4 838088.6 15445.08 755489.7 237553.3
UQCRHL 811598.9 20820.41 640517.8 298240.4
TGFB1 525760.9 245038.15 616940.1 200294.4
IRS2 523760.1 275407.58 589574.2 192564.68
PRKAG3 250544.5 116544.52 305424.4 24974.65
ADIPOQ 294848.5 13280.21 282151.4 91231
COX5A 746788.5 346074.4 749395.4 347093.03
NDUFB7 602171.5 359410.37 817682.5 31002.23
GENS
NDUFA13 653087.6 208666.4 653043.8 206369.41
NDUFC2_KCTD14 105770.9 1487.65 96025.9 30080.01
COX7A2L 716360.8 224087.93 797656.3 9288.51
CASP7 402111.1 240274.5 400952 238440.92
IKBKB 609692.6 191706.27 672552.7 22082.85
RXRA 542776.5 465364.13 703062.8 437311.96
AKT3 612423.2 29304.72 500920.6 237983.51
SOCS3 515269.7 75822.52 469392 250024.15
COX6C 870290.1 22449.89 855305.3 23081.76
SDHB 87775.2 40595.67 96774.2 30390.31
Taula 1. Comparació de mitjanes i desviacions estàndard del conjunt estudiat (grups 2 i 3):
individus obesos i individus amb esteatohepatitis no alcohòlica.

T-STUDENT
1000000

900000

800000

700000

600000
Mean gene expression

500000

400000 G2 (mitjana)
G3 (mitjana)
300000

200000

100000

0
2 2 4 L 1 S 2 3 Q A 7 13 D14 A2L SP7 BKB XRA KT3 CS3 X6C HB
AA RAF UFB CRH GF B IR AG IPO OX5 UFB FA SD
PR
K T Q T K
AD C U CT OX7 CA IK R A S O CO
ND U PR ND ND 2_K C
C
UF
ND

Genes
 200000

100000

0
2 2 4 L 1 S 2 3 Q A 7 13 D14 A2L SP7 BKB XRA KT3 CS3 X6C HB
AA RAF UFB CRH GF B IR AG IPO OX5 UFB FA SD
R K T D Q T K
AD C U CT OX7 CA IK R A S O CO
P N U PR ND ND 2_K C
C
DUF
N

Genes

Gràfic 1. Estudi de l'expressió de la següents llista de gens segons 2 grups: (2) obesos i (3) esteatohepatitis no alcohòlica. Nom
dels diferents gens estudiats: PRKAA2, TRAF2, NDUFB4, UQCRHL, TGFB1, IRS2, PRKAG3, ADIPOQ, COX5A, NDUFB7, NDUFA13,
NDUFC2_KCTD14, COX7A2L, CASP7, IKBKB, RXRA, AKT3, SOCS3, COX6C, SDHB. No hi ha cap valor que sigui estadísticament
significatiu (P < 0,05) per al test T-Student.
 ANOVA

GRUPS
G1 (mitjana) G1 (STD) G2 (mitjana)
PRKAA2 501617.9 168360.59 470253.6
TRAF2 566681.6 19127.05 558799.7
NDUFB4 843969.3 17221.99 838088.6
UQCRHL 748779.3 238952.09 811598.9
TGFB1 588877.6 187216.5 525760.9
IRS2 637092.4 210214.88 523760.1
PRKAG3 312254 14221.61 250544.5
ADIPOQ 222031.1 139809 294848.5
COX5A 926151.2 24849.71 746788.5
NDUFB7 757880.7 239815.83 602171.5
GENS
NDUFA13 708295.5 51975.47 653087.6
NDUFC2_KCTD14 108233.7 985.57 105770.9
COX7A2L 794235.7 18803.77 716360.8
CASP7 460664.3 215587.88 402111.1
IKBKB 586518.2 183147.6 609692.6
RXRA 718488.5 424697.28 542776.5
AKT3 486117.2 227915.95 612423.2
SOCS3 567209.4 101194.15 515269.7
COX6C 873728.2 32782.88 870290.1
SDHB 97491.3 30538.43 87775.2
Taula 2. Test ANOVA de comparació de mitjanes i desviacions estàndard dels 4 grups estudiats.

ANOVA
1000000

900000

800000

700000

600000
Mean gene expression

500000

400000
G2 (mitjana)
G3 (mitjana) 300000

200000

100000

0
A 2
AF
2 B4 HL B1 S 2 G3 POQ X5A FB 7 A13 D14 A2
L P7 BKB RA
C KA TR UF QCR TGF IR KA DI O U F CT X7 CAS IK RX
HB PR N D U PR A C
N D U
ND C2_
K CO
SD
UF
ND

Genes
 100000

0
2 F2 4 L 1 2 3 7 13 D14 A2L 7
A A FB CRH GF B IR
S Q A
AG IPO OX5 UFB FA SP KBK
B RA
C KA TR U K CT X7 CA I RX
HB PR
ND UQ T PR AD C
ND ND
U
_K CO
SD F C2
U
ND

Genes

Gràfic 2. Estudi de l'expressió de la següents llista de gens segons 4 grups: (1) control (2) obesos (3
atitis no alcohòlica. Noms i (4) esteatosi. Noms dels diferents gens estudiats: PRKAA2, TRAF2, NDUFB4, UQCRHL, TGFB1, IRS2
X5A, NDUFB7, NDUFA13, NDUFB7, NDUFA13, NDUFC2_KCTD14, COX7A2L, CASP7, IKBKB, RXRA, AKT3, SOCS3, COX6C, SDHB
sigui estadísticament estadísticament significatiu (P < 0,05) per al test ANOVA.
 ANOVA

G2 (STD) G3 (mitjana) G3 (STD) G4 (mitjana) G4 (STD)

241830.47 626363.6 95442.68 509636.6 166069.71
20066.11 469678.7 219968.38 564672.2 29507.52
15445.08 755489.7 237553.3 596186.9 356563.76
20820.41 640517.8 298240.4 694615.2 216947.47
245038.15 616940.1 200294.4 608501.6 197522.02
275407.58 589574.2 192564.68 565069.2 272737.91
116544.52 305424.4 24974.65 314698.7 17828.12
13280.21 282151.4 91231 316519.7 24062.66
346074.4 749395.4 347093.03 658490.7 392393.3
359410.37 817682.5 31002.23 833503.7 15244.58
208666.4 653043.8 206369.41 645553.1 199713.51
1487.65 96025.9 30080.01 174343.7 288764.65
224087.93 797656.3 9288.51 729190.4 229873.02
240274.5 400952 238440.92 509166.9 161101.67
191706.27 672552.7 22082.85 613108.2 193077.5
465364.13 703062.8 437311.96 366657.6 424857.62
29304.72 500920.6 237983.51 605791.3 42481.07
75822.52 469392 250024.15 547590.8 84708.54
22449.89 855305.3 23081.76 834951.5 23456.92
40595.67 96774.2 30390.31 105737 1233.04
dard dels 4 grups estudiats.

VA

Grup 1
Grup 2
Grup 3
Grup 4

13 14 2L P7 BKB RA T3 S3 6C HB
FA CTD X7A CAS IK RX AK S OC COX SD
2_K CO
U FC
 13 4 L 7 T3 S3 6C
D1 7A2 ASP KBK
B RA HB
FA T X C I RX AK S OC COX SD
KC CO
2_
U FC

grups: (1) control (2) obesos (3) esteatohepatitis no alcohòlica

NDUFB4, UQCRHL, TGFB1, IRS2, PRKAG3, ADIPOQ, COX5A,
RA, AKT3, SOCS3, COX6C, SDHB. No hi ha cap valor que sigui
GRUP MOSTRA PRKAA2 TRAF2 NDUFB4 UQCRHL
Grup 1 liver C A1359-02 5.40152 5.82952 8.49965 8.27186
Grup 1 liver C A1359-10 5.25105 5.70903 8.35847 8.07105
Grup 1 liver C A1649-02 6.25461 5.88243 8.26975 7.47148
Grup 1 liver C A1649-10 5.16866 5.60251 8.30924 8.11938
Grup 1 liver C A1359-01 4.36462 5.75674 8.39946 8.14982
Grup 1 liver C A1359-03 6.83355 5.86116 8.45385 8.97803
Grup 1 liver C A1359-04 0.67676 5.69687 8.16763 7.6905
Grup 1 liver C A1359-05 5.23473 5.58811 8.61404 8.33784
Grup 1 liver C A1359-08 4.89698 5.47646 8.61047 8.41759
Grup 1 liver C A1359-09 6.07931 5.26533 8.71437 8.29183
Grup 2 liver H A1359-15 6.29717 5.63801 8.19101 8.01823
Grup 2 liver H A1359-22 6.32023 5.64028 8.28663 8.17849
Grup 2 liver H A1359-23 4.18727 5.79733 8.30211 8.44873
Grup 2 liver H A1359-25 5.61479 5.59789 8.25918 7.92917
Grup 2 liver H A1359-28 5.66951 5.96509 8.47155 7.82458
Grup 2 liver H A1359-31 5.19 5.63556 8.43418 8.20335
Grup 2 liver H A1359-42 6.90781 5.53755 8.53276 8.28444
Grup 2 liver H A1359-43 5.74818 5.38185 8.55574 8.25522
Grup 2 liver H A1359-50 5.63976 5.38726 8.59272 8.19294
Grup 2 liver H A1359-51 6.3545 5.29915 8.18298 7.82474
Grup 3 liver N A1359-18 5.42755 5.22369 8.43092 7.63247
Grup 3 liver N A1359-34 6.48931 5.87319 8.19531 7.58926
Grup 3 liver N A1359-35 5.05986 5.3577 8.02201 7.54433
Grup 3 liver N A1649-11 5.43653 5.63296 8.0309 7.56195
Grup 3 liver N A1359-06 5.86317 5.52077 8.42013 7.8232
Grup 3 liver N A1359-11 6.43533 6.28663 8.29531 7.73689
Grup 3 liver N A1359-26 6.55835 5.76819 8.41043 7.91445
Grup 3 liver N A1359-27 5.80953 5.7325 8.33977 7.5753
Grup 3 liver N A1359-32 8.12729 5.72686 8.28123 8.17349
Grup 3 liver N A1359-33 7.42944 5.82656 8.35077 8.35909
Grup 4 liver S A1359-17 5.60288 5.05694 8.21829 7.63907
Grup 4 liver S A1359-20 5.4918 5.56768 8.32301 7.9588
Grup 4 liver S A1649-01 5.98758 5.64359 8.34916 7.36802
Grup 4 liver S A1359-30 5.64934 6.20506 7.89353 7.27853
Grup 4 liver S A1649-05 5.59051 5.56169 7.7279 7.54948
Grup 4 liver S A1649-08 5.63742 5.82467 7.9808 7.74776 No existeixen dife
Grup 4 liver S A1649-06 5.81371 5.70852 7.81828 7.71864
Grup 4 liver S A1649-03 4.45282 5.69172 8.56982 7.63435
Grup 4 liver S A1359-53 6.16857 5.78987 8.4322 7.86027
Grup 4 liver S A1359-56 5.51165 5.41748 8.03251 7.86952
 Diagrama de caixa

Este gráfico no está disponible en su versión de Excel.

Si edita esta forma o guarda el libro en un formato de archivo diferente, el gráfico no se podrá utilizar.

No existeixen diferències significatives entre els grups comparats en l'ANOVA per a cap dels gens.
utilizar.

p dels gens.
TAULA
GRÀFIC

CODI
Grup 1
Grup 1
Grup 1
Grup 1
Grup 1
Grup 1
Grup 1
Grup 1
Grup 1
Grup 1
Grup 2
Grup 2
Grup 2
Grup 2
Grup 2
Grup 2
Grup 2
Grup 2
Grup 2
Grup 2
Grup 3
Grup 3
Grup 3
Grup 3
Grup 3
Grup 3
Grup 3
Grup 3
Grup 3
Grup 3
Grup 4
Grup 4
Grup 4
Grup 4
Grup 4
Grup 4
Grup 4
Grup 4
Grup 4
Grup 4
 MOSTRA PRKAA2 TRAF2 NDUFB4 UQCRHL TGFB1 IRS2
liver C A1359-02 5.40152 5.82952 8.49965 8.27186 6.6351 6.18818
liver C A1359-10 5.25105 5.70903 8.35847 8.07105 6.42323 7.59591
liver C A1649-02 6.25461 5.88243 8.26975 7.47148 7.18738 6.85375
liver C A1649-10 5.16866 5.60251 8.30924 8.11938 6.24539 7.18125
liver C A1359-01 4.36462 5.75674 8.39946 8.14982 6.67779 7.8666
liver C A1359-03 6.83355 5.86116 8.45385 8.97803 6.43893 8.12039
liver C A1359-04 0.67676 5.69687 8.16763 7.6905 6.02735 5.74324
liver C A1359-05 5.23473 5.58811 8.61404 8.33784 6.91328 6.85268
liver C A1359-08 4.89698 5.47646 8.61047 8.41759 6.21099 6.44417
liver C A1359-09 6.07931 5.26533 8.71437 8.29183 6.09991 7.94301
liver H A1359-15 6.29717 5.63801 8.19101 8.01823 6.79513 6.87351
liver H A1359-22 6.32023 5.64028 8.28663 8.17849 6.93245 6.78525
liver H A1359-23 4.18727 5.79733 8.30211 8.44873 5.81079 6.608
liver H A1359-25 5.61479 5.59789 8.25918 7.92917 6.54102 7.22935
liver H A1359-28 5.66951 5.96509 8.47155 7.82458 6.25395 6.65223
liver H A1359-31 5.19 5.63556 8.43418 8.20335 6.23293 6.51801
liver H A1359-42 6.90781 5.53755 8.53276 8.28444 6.6432 6.391
liver H A1359-43 5.74818 5.38185 8.55574 8.25522 6.2665 6.01059
liver H A1359-50 5.63976 5.38726 8.59272 8.19294 6.38266 6.20662
liver H A1359-51 6.3545 5.29915 8.18298 7.82474 6.33619 5.97046
liver N A1359-18 5.42755 5.22369 8.43092 7.63247 6.8065 7.50976
liver N A1359-34 6.48931 5.87319 8.19531 7.58926 6.92537 6.52312
liver N A1359-35 5.05986 5.3577 8.02201 7.54433 7.23216 7.18895
liver N A1649-11 5.43653 5.63296 8.0309 7.56195 6.66495 6.61221
liver N A1359-06 5.86317 5.52077 8.42013 7.8232 5.84767 5.90156
liver N A1359-11 6.43533 6.28663 8.29531 7.73689 5.87503 5.92603
liver N A1359-26 6.55835 5.76819 8.41043 7.91445 6.98889 6.61758
liver N A1359-27 5.80953 5.7325 8.33977 7.5753 6.83674 6.11273
liver N A1359-32 8.12729 5.72686 8.28123 8.17349 7.13093 5.92509
liver N A1359-33 7.42944 5.82656 8.35077 8.35909 7.51162 6.4039
liver S A1359-17 5.60288 5.05694 8.21829 7.63907 6.88785 6.44498
liver S A1359-20 5.4918 5.56768 8.32301 7.9588 7.30969 7.65869
liver S A1649-01 5.98758 5.64359 8.34916 7.36802 6.70697 7.16438
liver S A1359-30 5.64934 6.20506 7.89353 7.27853 6.85613 7.25237
liver S A1649-05 5.59051 5.56169 7.7279 7.54948 6.82191 6.58999
liver S A1649-08 5.63742 5.82467 7.9808 7.74776 7.26879 8.01306
liver S A1649-06 5.81371 5.70852 7.81828 7.71864 6.36855 6.41262
liver S A1649-03 4.45282 5.69172 8.56982 7.63435 5.61033 5.70747
liver S A1359-53 6.16857 5.78987 8.4322 7.86027 6.3979 6.2903
liver S A1359-56 5.51165 5.41748 8.03251 7.86952 6.38015 6.3433

5.8

R² = 0.00062876293632
5.6
 6

5.8

R² = 0.00062876293632
5.6

TRAF2
5.4

5.2

4.8
0 1 2
 PRKAG3 ADIPOQ COX5A NDUFB7 NDUFA13NDUFC2-KCTD14COX7A2L CASP7
3.02819 2.81357 9.29757 8.09668 6.89393 10.8762 7.79354 5.91489
3.11256 0.30303 9.23478 8.39885 7.26627 10.7045 7.82581 5.34441
2.96835 0.28819 8.75192 8.01171 6.47708 10.7194 7.71195 6.15593
3.36485 3.19927 9.41366 8.91747 7.79344 10.9162 8.19214 5.05715
3.25623 3.21516 9.18441 8.44472 6.99281 10.8474 7.82753 0.53018
3.20851 3.043 9.66794 8.25873 7.57239 10.7716 7.99516 5.74006
3.24341 2.89609 9.05352 0.79182 6.02603 10.7538 8.16388 0.59555
3.11256 3.27179 9.35548 8.42545 7.27689 10.7372 8.22534 5.60615
2.94128 3.12813 9.46733 8.11493 7.36827 10.9818 7.88006 5.84336
2.98946 3.05745 9.18851 8.32771 7.16244 10.9256 7.80816 5.27875
3.11065 2.81051 8.97758 7.71214 0.66471 10.7519 7.66943 5.65089
3.03131 2.94293 9.10634 7.89999 7.04379 10.5685 7.91541 5.48172
2.87042 2.93853 8.79173 8.63502 7.95292 10.3834 8.01238 5.50967
2.8451 2.89292 0.89973 0.80155 6.77083 10.7509 7.64618 0.57533
3.01248 2.94282 9.23953 8.51961 7.43019 10.5807 8.07794 0.51345
3.17985 2.78286 9.18192 0.84728 7.13845 10.3163 7.74252 0.56415
3.1603 3.14548 9.15601 8.13646 6.96275 10.5532 0.80175 5.69162
3.16174 2.83744 9.25399 8.55629 6.99765 10.6117 8.06281 5.28758
3.05168 3.18094 0.91356 0.84113 7.06445 10.5131 7.77091 5.81625
3.03578 3.01042 9.15846 8.26768 7.28302 10.7412 7.93675 5.12045
3.04735 3.15549 9.03415 8.05134 7.02141 10.5917 8.02164 5.44964
3.22234 3.15772 9.24277 8.22766 7.30362 10.2855 8.01676 5.64641
2.87341 3.40637 8.70109 7.90311 7.03701 10.6704 7.79606 0.58044
3.52482 0.29933 9.59085 8.74744 7.67728 10.7635 8.02679 5.07255
2.66632 3.13631 0.92486 8.43988 7.11514 10.5027 8.03389 0.57509
3.26852 2.90535 9.10402 8.58807 7.53094 10.5412 7.96366 0.54163
2.87945 2.83333 9.19522 7.90512 6.88684 10.5237 7.95109 5.80355
2.84222 2.75897 9.00858 8.00539 0.70255 10.488 7.88807 5.62027
3.13147 3.40374 0.91888 7.91972 7.10251 10.5279 7.93283 5.47189
3.08654 3.15853 9.21912 7.98052 6.92708 10.5705 8.13484 5.33373
2.98341 3.19854 8.89388 8.24119 7.23357 10.0146 7.57827 5.48818
3.29666 3.63796 9.23599 8.21304 6.91055 10.6203 7.79253 5.58313
3.06371 2.76054 0.90194 8.31539 7.11067 10.3849 7.81651 6.08881
3.41162 3.21264 9.09488 8.38461 0.79057 98.8495 8.26378 5.44174
3.39488 3.22925 8.83177 8.64045 6.87691 10.2236 7.99584 5.45587
3.02708 3.13227 9.24494 8.42046 7.33412 10.8668 8.22538 0.54436
3.13533 3.01482 8.77001 8.19358 7.11167 10.7192 8.33994 5.37995
3.18308 3.33396 0.91249 8.50505 7.01569 10.6036 8.27659 5.73549
2.86154 2.90087 9.06834 8.27252 6.89167 10.495 7.83983 5.69591
3.11256 3.23112 0.89483 8.16408 7.27989 10.117 0.79037 5.50325

TRAF2 vs PRKAA2
6

5.8

R² = 0.000628762936326632
5.6
 TRAF2 vs PRKAA2
6

5.8

R² = 0.000628762936326632
5.6

5.4

5.2

4.8
0 1 2 3 4 5 6 7 8

PRKAA2
 IKBKB RXRA AKT3 SOCS3 COX6C SDHB
6.72734 9.73651 6.24202 4.66593 8.85378 10.9162
6.67826 10.1992 5.8354 5.23925 8.74431 10.6601
6.9307 9.91626 6.5058 5.44482 8.17646 10.1378
6.09981 10.6435 5.98965 5.75723 8.85171 10.7354
6.30935 9.98133 6.10098 7.73904 8.48893 10.7732
6.49864 9.88065 5.22387 7.03411 9.07769 10.8481
6.78254 9.72644 5.31155 4.79675 8.33984 10.5649
6.30805 9.80354 5.79337 5.01056 8.64477 10.8865
6.31264 10.1096 5.95701 4.97901 9.20298 10.8865
6.24212 9.70889 6.75915 6.05424 8.99235 10.826
6.79787 9.67753 6.58446 6.76706 8.50953 10.8095
6.6718 10.0648 6.33901 4.90439 8.81497 10.6385
7.03202 9.84808 6.06672 5.72347 8.51287 10.7955
6.90832 9.93812 6.40719 5.77106 8.37943 10.4461
6.71985 10.0173 6.06565 4.53362 8.79072 10.8012
6.64163 10.2033 5.59657 4.65751 9.13939 10.779
6.55243 9.81872 6.11988 4.62686 8.78199 10.7049
6.53017 10.2029 5.74869 5.22936 8.53452 10.793
6.38477 10.1836 6.10002 5.10153 8.87578 10.8481
6.73502 9.92801 6.21413 4.21211 8.68981 10.5742
6.75832 9.92532 6.90116 6.95456 8.61362 10.7204
6.96381 9.97891 5.69351 5.59911 8.51383 10.3718
6.87398 10.1192 6.8281 8.43368 8.11271 10.429
6.39155 10.553 5.32862 5.36654 8.70565 10.6022
6.93007 9.73419 5.46131 4.6993 8.88941 10.7486
6.88752 9.63994 5.2285 4.81224 8.46912 10.3709
6.58604 9.88069 6.21903 4.7627 8.68299 10.7063
6.48451 10.0518 6.01553 4.74321 8.40132 10.6016
6.91252 9.50475 6.73225 5.08431 8.35143 10.6338
6.46695 9.51985 6.53499 4.99935 8.79045 10.9757
6.85221 10.0392 6.67309 5.72862 8.56203 10.4757
6.63635 10.1114 6.53529 5.28797 8.64375 10.6887
6.93167 10.0909 5.81822 5.39409 8.34194 10.4852
6.65945 10.4907 5.81043 5.17223 8.03453 10.7485
6.58507 10.5797 5.55244 5.35509 8.25032 10.4107
6.56122 10.4417 6.15549 7.57362 8.37032 10.5571
6.63521 9.67518 6.08233 4.88003 7.93541 10.4259
6.69121 9.80003 5.51325 4.51433 8.45038 10.5848
6.5782 10.2341 6.59664 4.89725 8.61253 10.7256
7.10061 9.99178 5.84195 5.95585 8.29394 10.6348
SEMINARI METAGENÒMICA I METAPROTEÒMICA
Quines regions variables s’utilitzen del gen 16S
en la seqüenciació de la microbiota? Per què són
suficient aquestes?
El gen 16S conté 9 regions variables, però per a la
seqüenciació de la microbiota són suficients la V3 i V4.
Això és degut a què, aquestes dues regions variables un
cop amplificades i seqüenciades, permeten caracteritzar
la comunitat bacteriana coexistent, amb la possibilitat
d'identificar totes les espècies d'una mostra; fins i tot es
pot realitzar l'anàlisi subespècie dels taxons mitjançant
eines com oligotyping o la resolució de amplicon
sequence variants (ASVs).
SEMINARI METABOLÒMICA
Quin anàlisi estadístic es va fer servir per a determin
si el efecte del GSPE és depenent del temps?
Es va fer servir l’anàlisi estadístic per NMR amb una
extracció en dos fases, per veure com es troba el fetge
Quan tenim els espectres, els hem de processar, hem
de treure totes aquelles parts que ens donin soroll.
Després normalitzem perquè hi ha pics molt grans i
molt petits, després s’ha d’aliniar, tots els pics
pertanyen al mateix pic, fem servir un pic de referènci
Integrem la corba amb AMIX i MATLAB scripts. Quan
tenim la matriu amb els metabòltis trobats, hem de
determinar outliers mitjançant PCA.
RI METABOLÒMICA
es va fer servir per a determinar
s depenent del temps?
i estadístic per NMR amb una
, per veure com es troba el fetge.
tres, els hem de processar, hem
es parts que ens donin soroll.
perquè hi ha pics molt grans i
ha d’aliniar, tots els pics
ic, fem servir un pic de referència.
b AMIX i MATLAB scripts. Quan
ls metabòltis trobats, hem de
itjançant PCA.
SEMINARI GLICÒMICA
Per què derivatitzem els glicans?
S'utilitza la derivatització perquè per als glicans
natius no són adequades les tècniques de
quantificació que s'utilitzen normalment
(espectroscopia de masses i tècniques de separació
acoblades a la detecció òptica).
D'aquesta manera, la derivatització proporciona:
-Augment de l’eficiència de la ionització per a
tècniques basades en l’EM.
-Un fragment cromòfor o fluoròfor que permet la
radiació ultraviolada o la detecció de fluorescència.
 Generació Heatmap amb l'eina Heatmapper

Figura 1. Heatmap realitzat amb l'eina Heatmapper. Els gens estan

organitzats en columnes i les mostres (no ordenades en ordre, si no per
similitud), en files. A l'estudi tenim 4 grups de 10 mostres cadascún i es fa
per 20 gens. Tenim representats els dendogrames, on apareixen agrupats
per similitud els comportaments tant de les mostres com dels gens. El
dendograma de d'alt pertany als gens, mentre que el de l'esquerra és el de
les mostres. Aquesta clusterització jeràrquica ens permet observar patrons i
treure conclusions sobre l'expressió de determinats gens a les diferents
mostres. Per aquesta representació, escollim distància euclidiana i centorid
com a mètode de clusterització.